Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Stacchiotti, S; Sommer, J; Chordoma Global Consensus Group.
Building a global consensus approach to chordoma: a position paper from the medical and patient community.
Lancet Oncol. 2015; 16(2):e71-e83
Doi: 10.1016/S1470-2045(14)71190-8
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
-
Leithner Andreas
-
Scheipl Susanne
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Chordomas are very rare bone malignant tumours that have had a shortage of effective treatments for a long time. New treatments are now available for both the local and the metastatic phase of the disease, but the degree of uncertainty in selecting the most appropriate treatment remains high and their adoption remains inconsistent across the world, resulting in suboptimum outcomes for many patients. In December, 2013, the European Society for Medical Oncology (ESMO) convened a consensus meeting to update its clinical practice guidelines on sarcomas. ESMO also hosted a parallel consensus meeting on chordoma that included more than 40 chordoma experts from several disciplines and from both sides of the Atlantic, with the contribution and sponsorship of the Chordoma Foundation, a global patient advocacy group. The consensus reached at that meeting is shown in this position paper.
Copyright © 2015 Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
-
Bone Neoplasms - diagnosis
-
Bone Neoplasms - therapy
-
Chordoma - diagnosis
-
Chordoma - therapy
-
Humans -
-
Medical Oncology - standards
-
Patient Advocacy -
-
Practice Guidelines as Topic -